NCT05157698View on ClinicalTrials.gov

Pharmacological and Behavioral Treatment After Bariatric Surgery

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

January 12, 2027

Study Completion Date

January 12, 2028

Conditions
Obesity
Interventions
DRUG

Naltrexone and Bupropion Combination

Participants in this intervention will take active naltrexone and bupropion pills.

BEHAVIORAL

Behavioral Weight Loss

Participants in this intervention will receive behavioral weight loss treatment.

OTHER

Placebo

Participants in this intervention will take inactive (placebo) pills.

Trial Locations (1)

06519

RECRUITING

Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER